Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
BCG Vaccine is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Lead Product(s): BCG Vaccine,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Vaccine
Sponsor: University of Southern Denmark | Radboud University Medical Center
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2025
Lead Product(s) : BCG Vaccine,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : University of Southern Denmark | Radboud University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
BCG Revaccination with Third DTP Dose & Infant Mortality in Africa
Details : BCG Vaccine is a Vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 05, 2025
Details:
Imfinzi (durvalumab) is a PDL-1 inhibitor of IgG1 type, being investigated for the treatment of high-risk non-muscle-invasive bladder cancer.
Lead Product(s): Durvalumab,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Imfinzi
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2025
Lead Product(s) : Durvalumab,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imfinzi Boosts Disease-Free Survival in High-Risk NMIBC in POTOMAC Trial
Details : Imfinzi (durvalumab) is a PDL-1 inhibitor of IgG1 type, being investigated for the treatment of high-risk non-muscle-invasive bladder cancer.
Product Name : Imfinzi
Product Type : Antibody
Upfront Cash : Inapplicable
May 09, 2025
Details:
Anktiva (nogapendekin alfa inbakicept) is an IL-15 receptor agonist indicated with BCG for the treatment of adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.
Lead Product(s): Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2025
Lead Product(s) : Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunityBio Seeks Urgent FDA Meet After sBLA Filing Refusal for NMIBC
Details : Anktiva (nogapendekin alfa inbakicept) is an IL-15 receptor agonist indicated with BCG for the treatment of adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
May 05, 2025
Details:
Anktiva (nogapendekin alfa inbakicept) is a IL-15 receptor agonist, it is being investigated for BCG-unresponsive high grade non-MIBC in combination with Bacillus Calmette-Guérin.
Lead Product(s): Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunityBio Files sBLA for NMIBC and ANKTIVA Access
Details : Anktiva (nogapendekin alfa inbakicept) is a IL-15 receptor agonist, it is being investigated for BCG-unresponsive high grade non-MIBC in combination with Bacillus Calmette-Guérin.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
April 15, 2025
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus BCG for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma.
Lead Product(s): Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2024
Lead Product(s) : Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunityBio’s ANKTIVA Achieves 71% Response in NMIBC CIS Trial with Long Durability
Details : Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus BCG for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
November 19, 2024
Details:
Anktiva (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor agonist, evaluated with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer treatment.
Lead Product(s): Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2024
Lead Product(s) : Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunityBio Receives FDA Approval for ANKTIVA® in Bladder Cancer Treatment
Details : Anktiva (nogapendekin alfa inbakicept-pmln) is an IL-15 receptor agonist, evaluated with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer treatment.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
April 22, 2024
Details:
Anktiva (nogapendekin alfa inbakicept) is an IL-15 receptor agonist indicated with BCG for the treatment of adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.
Lead Product(s): Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 07, 2024
Lead Product(s) : Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UK MHRA Approves ANKTIVA® Plus BCG for BCG-Unresponsive NMIBC Carcinoma In Situ
Details : Anktiva (nogapendekin alfa inbakicept) is an IL-15 receptor agonist indicated with BCG for the treatment of adults with BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
February 07, 2024
Details:
Proceeds will also support N-803 (Anktiva), an interleukin-15 superagonist fusion protein, currently in clinical trials for solid tumors including BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Protein
Sponsor: Oberland Capital Management
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 01, 2024
Lead Product(s) : Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Oberland Capital Management
Deal Size : $320.0 million
Deal Type : Financing
ImmunityBio Secures $320 Million Investment, Totaling $850 Million in 2023
Details : Proceeds will also support N-803 (Anktiva), an interleukin-15 superagonist fusion protein, currently in clinical trials for solid tumors including BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Undisclosed
February 01, 2024
Details:
The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Protein
Sponsor: Nant Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 09, 2023
Lead Product(s) : Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Nant Capital
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invas...
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Undisclosed
November 09, 2023
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2023
Lead Product(s) : Nogapendekin Alpha Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
Details : Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease...
Product Name : Anktiva
Product Type : Protein
Upfront Cash : Inapplicable
October 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
